agilon health (AGL) Competitors

DaVita (NYSE:DVA) and agilon health (NYSE:AGL) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.

Which has more risk & volatility, DVA or AGL?

DaVita has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, agilon health has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

Does the media prefer DVA or AGL?

In the previous week, DaVita had 10 more articles in the media than agilon health. MarketBeat recorded 16 mentions for DaVita and 6 mentions for agilon health. DaVita's average media sentiment score of 0.87 beat agilon health's score of 0.48 indicating that DaVita is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	4 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
agilon health	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings and valuation, DVA or AGL?

DaVita has higher revenue and earnings than agilon health. agilon health is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$11.61 billion	0.77	$560.40 million	$5.42	18.30
agilon health	$3.19 billion	2.69	-$106.55 million	-$0.22	-94.09

Do analysts rate DVA or AGL?

DaVita presently has a consensus target price of $96.88, indicating a potential downside of 2.30%. agilon health has a consensus target price of $31.13, indicating a potential upside of 50.36%. Given agilon health's stronger consensus rating and higher possible upside, analysts clearly believe agilon health is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
agilon health	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Is DVA or AGL more profitable?

DaVita has a net margin of 4.40% compared to agilon health's net margin of -2.88%. DaVita's return on equity of 72.08% beat agilon health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	4.40%	72.08%	3.59%
agilon health	-2.88%	-7.98%	-4.54%

Does the MarketBeat Community believe in DVA or AGL?

DaVita received 443 more outperform votes than agilon health when rated by MarketBeat users. Likewise, 61.83% of users gave DaVita an outperform vote while only 60.32% of users gave agilon health an outperform vote.

Company	Underperform	Outperform
DaVita	Outperform Votes 481 61.83%	Underperform Votes 297 38.17%
agilon health	Outperform Votes 38 60.32%	Underperform Votes 25 39.68%

Do institutionals and insiders believe in DVA or AGL?

86.5% of DaVita shares are held by institutional investors. 1.4% of DaVita shares are held by insiders. Comparatively, 3.6% of agilon health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

DaVita beats agilon health on 12 of the 18 factors compared between the two stocks.